Alexion

Alexion joins with Dicerna to develop RNAi therapies for complement diseases

https://pharmaphorum.com/news/alexion-joins-with-dicerna-to-develop-rnai-therapies-for-complement-diseases/

Alexion buys rare diseases biotech Syntimmune for up to $1.2bn

https://pharmaphorum.com/news/alexion-buys-rare-diseases-biotech-syntimmune-for-up-to-1-2bn/

Alexion prepares filings for new rare disease use for Soliris

https://pharmaphorum.com/news/alexion-prepares-filings-for-new-rare-disease-use-for-soliris/

Alexion hastens review of successor to rare disease blockbuster Soliris

https://pharmaphorum.com/news/alexion-hastens-review-of-successor-to-rare-disease-blockbuster-soliris/

Alexion’s Soliris successor aces two phase 3 trials

https://pharmaphorum.com/news/alexions-soliris-successor-aces-two-phase-3-trials/

Alexion bids $855m for rare disease biotech Wilson Therapeutics

https://pharmaphorum.com/news/alexion-buy-rare-disease-biotech-wilson-therapeutics/

Alexion to file successor to rare diseases drug Soliris

https://pharmaphorum.com/news/alexion-shares/

Myasthenia Gravis approval will boost Soliris revenues

https://pharmaphorum.com/news/myasthenia-gravis-approval-will-boost-soliris-revenues/

Alexion cuts ties with Moderna and re-focuses

https://pharmaphorum.com/news/alexion-cuts-ties-moderna-re-focuses/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search